Intravenous iron therapy in renal failure: friend and foe?

J Nephrol. Jul-Aug 2004;17(4):487-95.

Abstract

Anemia is a common feature of chronic renal dysfunction and is associated with significant morbidity and mortality. Although acquired insufficiency of erythropoietin is virtually universal, iron deficiency is also a common contributor to the development of anemia. Iron replacement, in particular via the intravenous route, has become commonplace and results in improved hematocrits either on its own or in association with an erythropoiesis stimulating agent. However, intravenous iron is not without its potential complications. These include acute allergic reactions, iron overload, potentially accelerated cardiovascular disease and risk of infection. It is the purpose of this review to critically evaluate the available clinical and experimental evidence linking iron supplementation therapy with these complications.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Anemia, Iron-Deficiency / drug therapy*
  • Anemia, Iron-Deficiency / etiology
  • Animals
  • Drug Hypersensitivity / etiology*
  • Drug Hypersensitivity / prevention & control
  • Female
  • Follow-Up Studies
  • Humans
  • Infusions, Intravenous
  • Iron Compounds / administration & dosage*
  • Iron Compounds / adverse effects
  • Iron Overload / prevention & control*
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / therapy*
  • Male
  • Renal Dialysis / adverse effects*
  • Renal Dialysis / methods
  • Risk Assessment
  • Treatment Outcome

Substances

  • Iron Compounds